Switching HIV therapies: competing host and viral factors

The Lancet

Volumn 375, Issue 9712, 2010, Pages 352-354

  Kilby, J Michael ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTEGRASE INHIBITOR; LOPINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG INDICATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOATROPHY; LOW DRUG DOSE; NEUROPATHY; PANCREATITIS; PRIORITY JOURNAL; SURVIVAL; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS RESISTANCE;

EID: 75149131558     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60067-0     Document Type: Note

References (11)

1. Eron J.J., Young B., Cooper D.A., et al., for the SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet (2010) 10.1016/S0140-6736(09)62041-9 published online Jan 13.
2. Gulick R.M., Mellors J.W., Havlir D., et al. Treatment with indinavir, zidovudine and lamivudine in adults with HIV infection and prior antiretroviral therapy. N Engl J Med 337 (1997) 734-739
3. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 338 (1998) 853-860
4. Elmer-Dewitt P. Turning the tide. Time (Dec 30, 1996) 54
5. Hammer S.M., Eron J.J., Reiss P., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 300 (2008) 555-570
6. Shlay J.C., Bartsch G., Peng G., et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomised to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor- or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based therapy. J Acquir Immune Defic Syndr 44 (2008) 506-517
7. Riddler S.A., Haubrich R., DiRienzo A.G., et al., for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358 (2008) 2095-2106
8. Hirsch M.S., Gunthard H.F., Schapiro J.M., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 16 (2008) 266-285
9. Grinsztejn B., Nguyen B.Y., Katlama C., et al., for the Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug resistant virus: a phase II randomised controlled trial. Lancet 369 (2007) 1261-1269
10. Markowitz M., Nguyen B.Y., Gotuzzo E., et al., the the Protocol 004 Part II Study Team. Rapid and durable antiretroviral effects of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46 (2007) 125-133
11. Lennox J.L., DeJesus E., Lazzarin A., et al., for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-inaive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374 (2009) 796-806